Comparative Pharmacology
Head-to-head clinical analysis: DUO MEDIHALER versus LUSEDRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUO MEDIHALER versus LUSEDRA.
DUO-MEDIHALER vs LUSEDRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone propionate, a corticosteroid with anti-inflammatory activity, and salmeterol, a long-acting beta2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle by stimulating intracellular adenyl cyclase, increasing cyclic AMP levels.
LUSEDRA (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces presynaptic dopamine release by inhibiting VMAT2, thereby reducing dopamine neurotransmission in the striatum.
Two inhalations (50 mcg ipratropium bromide and 100 mcg fenoterol hydrobromide per inhalation) four times daily via metered-dose inhaler.
5 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life of 3-4 hours for the bronchodilator component and 6-8 hours for the corticosteroid component; clinically requires twice-daily dosing.
8-12 hours (terminal, prolonged in renal impairment; dose adjustment needed if CrCl <30 mL/min).
Renal: 70-80% (free drug and metabolites), Biliary/Fecal: 10-20%
Primarily renal (70-80% as unchanged drug); 20-30% via biliary/fecal.
Category C
Category C
Anticholinergic/Beta2-Agonist Combination
Anticholinergic